BioNTech appoints Sobi head Guido Oelkers as new CEO to steer oncology shift
BioNTech announced that Guido Oelkers, who has led the rare‑disease focused Swedish company Sobi since 2017, will become its next chief executive officer.
Oelkers is slated to take over the role by Feb 1 2027, succeeding co‑founder and former CEO Ugur Sahin. Sahin will depart BioNTech to run a new, unnamed mRNA startup, and the company is also seeking a replacement for co‑founder and chief medical officer Özlem Türeci, who will join Sahin at the new venture.
The leadership change is part of BioNTech’s broader transformation from a general messenger RNA developer into a more oncology‑focused biotech, building on its high‑profile COVID‑19 vaccine partnership with Pfizer.
This writeup was produced by pharmadog from original reporting by BioPharma Dive.
Original headline: “BioNTech taps Sobi executive Oelkers as its next CEO”
read at BioPharma Dive ↗
comments(0)
5-min edit window · permanent after that